Sir, We also read with interest the manuscript by Castanheira et al.
Sir, We also read with interest the manuscript by Castanheira et al. 1 that confirms our data regarding the importance of the L3 loop (and specifically the Arg228Ser replacement) in the evolution of the activity of VIM-type enzymes. 2 We would suggest that differences in MIC values between the pairs VIM-1/VIM-13 and VIM-2/VIM-23 for specific antibiotics may be due to the structural and genetic differences in the L3 loop of both groups of enzymes: for example, a valine for isoleucine at position 223 and leucine/histidine for tyrosine at position 224, between VIM-1/VIM-13 and VIM-2/VIM-23 groups, respectively.
It is also important to note that differences in ceftazidime and cefepime MIC conferred by VIM-2 and VIM-23 were 4-fold, which was much lower than the 12-fold and 64-fold differences in ceftazidime and cefepime, respectively, conferred by VIM-1 and VIM-13. For these reasons it would be interesting to perform biochemical experiments with VIM-23 b-lactamase to assess kinetic parameters towards these antibiotics.
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Sir, We would like to thank Valvatne et al. 1 for their study of isoniazid and rifampicin resistance in Mycobacterium tuberculosis isolates from Yangon, Myanmar. In 9.4% of their isolates they identified a G to A mutation at position 288 with respect to the start codon of ahpC (Rv2428), which corresponds to position 246 with respect to the translational start site. We note that this mutation is not a marker for isoniazid resistance, which increases the proportion of isolates from the study by Valvatne et al.
1 for which resistance cannot be accounted for genotypically. 2 Instead, it constitutes a potential marker for lineage 3 [Central Asian (CAS)] strains of the M. tuberculosis complex (MTBC).
2,3
Moreover, we would like to comment on the mutation identified in 34.4% of their isolates in oxyR ′ (Rv2427A). First, we note that oxyR ′ is a pseudogene and, as a result, translating the mutation is not appropriate. Second, the translation provided is not valid given that oxyR ′ is actually located on the reverse strand. Third, and last, the C to T mutation is a known marker for lineage 1 [East African-Indian (EAI)] strains of MTBC and is not specific for isoniazid resistance. 3, 4 The association of both of these mutations with defined phylogenetic groups has recently been confirmed by the M. tuberculosis Phylogeographic Diversity Sequencing Project, which sequenced 31 strains to cover the global diversity of MTBC. 3, 5 As expected, all EAI strains (K21, K67, K93, T17, T83, T92 and 95 0545) contained the oxyR ′ mutation, whereas all CAS strains (K49, SG1 and 91 0079) harboured the ahpC mutation. 3, 5 Letters to the Editor The frequencies of both mutations, and hence the frequencies of the corresponding lineages in the study by Valvatne et al.,
1 are in line with spoligotyping data from another study that analysed strains from the same year and sample location, and found that 4.8% and 48.4% of isolates belonged to the CAS lineage and the EAI lineage, respectively. Sir, We thank Kö ser et al. 1 for their valuable comments on our paper 2 and note with interest the association of specific single nucleotide polymorphisms (SNPs) with Mycobacterium tuberculosis strain lineages; the mutation at position -46 in the oxyR -ahpC intergenic region with the Central Asian (CAS) lineage and the C to T mutation in oxyR with East African -Indian (EAI) lineage strains. This corroborates some of our own recent observations 3 in a study conducted in a country that neighbours Myanmar (India), where we showed by SNP analysis of the pncA gene (conferring resistance to pyrazinamide) a CAS lineage-specific silent mutation, S65S, which is observed for the majority of CAS lineage isolates. There seems to be a somewhat mixed view with regard to the role of the frequent mutation in the oxyR-ahpC intergenic region at position -46. In a study by Baker et al., 4 among 378 strains, the oxyR-ahpC mutation was present in 23.7% of isoniazid-resistant isolates and 7.5% of susceptible isolates. Although a phylogenetic marker for a subgroup of M. tuberculosis strains originating on the Indian subcontinent (CAS), this marker is strongly associated with isoniazid resistance and the katG 315Thr mutation.
